Search Videos by Topic or Participant
Browse by Series:

Carfilzomib Combination in Relapsed Multiple Myeloma

Panelists: James R. Berenson, MD, IMBCR; Sundar Jagannath, MD, Tisch Cancer Institute; Shaji Kumar, MD, Mayo; Sagar Lonial, MD, Emory; A. Kei
Published: Friday, Feb 20, 2015
For High-Definition, Click
The ASPIRE trial compared carfilzomib, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed multiple myeloma (MM), describes Sagar Lonial, MD. The median progression-free survival (PFS) was 26.3 with carfilzomib versus 17.6 months without (HR = 0.69; 95% CI, 0.57-0.83; P <.0001). Sundar Jagannath, MD, notes that these results clearly demonstrated that the triple therapy regimen is superior to doublet therapy in a relapsed situation.

In the control arm of the ASPIRE trial, the long remissions seen with lenalidomide and dexamethasone were unprecedented, suggests James R. Berenson, MD. Another outstanding result of ASPIRE was the comparability of the side effect profile between the 2 study arms, suggests Shaji Kumar, MD.

In the FOCUS trial, which was conducted predominantly in Europe, patients were randomized to receive either single agent carfilzomib or cyclophosphamide and prednisone. The 2 arms were similar in PFS and overall survival outcomes, reports Lonial. Each of these agents are associated with unique side effects, panelists note.
Slider Left
Slider Right
For High-Definition, Click
The ASPIRE trial compared carfilzomib, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed multiple myeloma (MM), describes Sagar Lonial, MD. The median progression-free survival (PFS) was 26.3 with carfilzomib versus 17.6 months without (HR = 0.69; 95% CI, 0.57-0.83; P <.0001). Sundar Jagannath, MD, notes that these results clearly demonstrated that the triple therapy regimen is superior to doublet therapy in a relapsed situation.

In the control arm of the ASPIRE trial, the long remissions seen with lenalidomide and dexamethasone were unprecedented, suggests James R. Berenson, MD. Another outstanding result of ASPIRE was the comparability of the side effect profile between the 2 study arms, suggests Shaji Kumar, MD.

In the FOCUS trial, which was conducted predominantly in Europe, patients were randomized to receive either single agent carfilzomib or cyclophosphamide and prednisone. The 2 arms were similar in PFS and overall survival outcomes, reports Lonial. Each of these agents are associated with unique side effects, panelists note.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x